Galera Therapeutics (NASDAQ:GRTX) Trading Up 7.3% Following Insider Buying Activity

Galera Therapeutics (NASDAQ:GRTX)’s stock price was up 7.3% during trading on Tuesday after an insider bought additional shares in the company. The company traded as high as $14.77 and last traded at $13.69, approximately 178,400 shares traded hands during mid-day trading. An increase of 5% from the average daily volume of 169,200 shares. The stock had previously closed at $12.76.

Specifically, insider Holdings A/S Novo acquired 500,000 shares of the stock in a transaction on Tuesday, November 12th. The shares were bought at an average price of $12.76 per share, with a total value of $6,380,000.00. Also, major shareholder Enterprise Associates 14 New acquired 416,666 shares of the stock in a transaction on Tuesday, November 12th. The shares were bought at an average cost of $11.79 per share, for a total transaction of $4,912,492.14.

Galera Therapeutics Company Profile (NASDAQ:GRTX)

Galera Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis.

Recommended Story: What is the role of the G-20?

Receive News & Ratings for Galera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.